Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Epigenetic Priming By Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-Cell Lymphoma

George Ward, Zhiqiang Zhang, Simone Jueliger, Ilya Potapov, Matthew P Davis, Adam Boxall, Jason A Taylor, Harold N. Keer, Andrea Biondo, John F Lyons, Martin Sims, Tomoko Smyth

Blood (2023) 142 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2023-186712

Published: 2023

Journal Articles

Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma

George A. Ward, Simone Jueliger, Martin Sims, Matthew Davis, Adam Boxall, Harpreet Saini, Jason A. Taylor, Andrea Biondo, John F. Lyons, Tomoko Smyth

Blood (2021) 138 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2021-152176

Published: 2021

Journal Articles

Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models

Christopher J. Hindley, PhD, Lynsey Fazal, BSc, Joanne M. Munck, PhD, Vanessa Martins, BSc, Alpesh D. Shah, MSci, Nicola E. Wilsher, PhD, Nicola G. Wallis, PhD, Harold N. Keer, MDPhD, John F. Lyons, PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-139175

Published: 2020

Journal Articles

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

Matthew D. Seftel, MDMPH FRCPC, John Kuruvilla, MD, Versha Banerji, MD, Graeme Fraser, MDFRCPC, Hao Xu, MSc, Jean Powers, MSc, Susan Crocker, PhD, Marcia Toguchi, PhD, John F Lyons, PhD, Lesley Seymour, MDPhD, Annette E Hay, MB ChB

Blood (2014) 124 (21): 5670.

https://doi.org/10.1182/blood.V124.21.5670.5670

Published: 2014

Journal Articles

Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML)

Simone Jueliger, PhD, John F Lyons, PhD, Joern Lewin, PhD, Mohammad Azab, MD, Pietro Taverna, PhD

Blood (2014) 124 (21): 1050.

https://doi.org/10.1182/blood.V124.21.1050.1050

Published: 2014

Journal Articles

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Annette E Hay, MB ChB, Alli Murugesan, PhD, Ashley M. DiPasquale, BSc, Tom Kouroukis, MD MSc, FRCPC, Irwindeep Sandhu, MD FRCPC, Vishal Kukreti, MD, Nizar J Bahlis, MD, Johan Lategan, MD, Donna E. Reece, MD, John F. Lyons, PhD, Joana Sederias, MSc, Jean Powers, MSc, Hao Xu, MSc, Lesley K. Seymour, MD PhD FRCP (C), Anthony Reiman, MD

Blood (2014) 124 (21): 5734.

https://doi.org/10.1182/blood.V124.21.5734.5734

Published: 2014

Journal Articles

Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study

Woonbok Chung, PhD, Pietro Taverna, PhD, John F Lyons, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Patricia Kropf, MD, Jean-Pierre Issa, MD

Blood (2013) 122 (21): 1442.

https://doi.org/10.1182/blood.V122.21.1442.1442

Published: 2013

Journal Articles

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Noopur Raje, MD, Parameswaran N. Hari, MD, MRCP, MS, Heather Landau, MD, Paul G. Richardson, MD, Jacalyn Rosenblatt, MD, Nicole Couture, RN, John F. Lyons, PhD, Gillian Langford, PhD, Murray Yule, MD

Blood (2013) 122 (21): 1976.

https://doi.org/10.1182/blood.V122.21.1976.1976

Published: 2013

Journal Articles

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells

Ruriko Tanaka, Matthew S. Squires, Shinya Kimura, Asumi Yokota, Rina Nagao, Takahiro Yamauchi, Miki Takeuchi, Hisayuki Yao, Matthias Reule, Tomoko Smyth, John F. Lyons, Neil T. Thompson, Eishi Ashihara, Oliver G. Ottmann, Taira Maekawa

Blood (2010) 116 (12): 2089–2095.

https://doi.org/10.1182/blood-2009-03-211466

Published: 2010

Includes: Supplemental data

Journal Articles

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

John F Lyons, PhD, Matthew S Squires, John Goodall, Murray Yule, Farhad Ravandi, MD, James Foran, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 4159.

https://doi.org/10.1182/blood.V114.22.4159.4159

Published: 2009

Journal Articles

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

Vicky Lock, Laurence Cooke, Murray Yule, Neil T Thompson, K. Della Croce, John F Lyons, Matthew S Squires, Daruka Mahadevan

Blood (2008) 112 (11): 3161.

https://doi.org/10.1182/blood.V112.11.3161.3161

Published: 2008

Journal Articles

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

John Goodall, Matthew S Squires, Vicky Lock, Farhad Ravandi, MBBS, Hagop M Kantarjian, James Foran, MD, Neil T Thompson, John F Lyons

Blood (2008) 112 (11): 1613.

https://doi.org/10.1182/blood.V112.11.1613.1613

Published: 2008

Journal Articles

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

Ruriko Tanaka, MMSc, Matthew S Squires, PhD, Shinya Kimura, MD, PhD, Asumi Yokota, MMSc, Kirsty Mallett, PhD, Tomoko Smyth, PhD, Neil T Thompson, PhD, Rina Nagao, Takahiro Yamauchi, MD, Takashi Ushiki, MD, John F Lyons, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 1104.

https://doi.org/10.1182/blood.V112.11.1104.1104

Published: 2008

Journal Articles

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

Matthew S. Squires, PhD, Ruth E. Feltell, BSc, Victoria Lock, Donna M. Smith, PhD, Jon E. Lewis, Jacqueline Higgins, Murray Yule, MD, Neil T. Thompson, PhD, Laurence Cooke, Kimiko D. Croce, Wenqing Qi, John F. Lyons, PhD, Daruka Mahadevan

Blood (2007) 110 (11): 3127.

https://doi.org/10.1182/blood.V110.11.3127.3127

Published: 2007

Journal Articles

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Matthew S. Squires, PhD, Jayne E. Curry, Mark A. Dawson, Mike A. Scott, Kelly Barber, Matthias Reule, Tomoko Smyth, Nicola Wallis, Murray Yule, Neil T. Thompson, John F. Lyons, Anthony R. Green

Blood (2007) 110 (11): 3537.

https://doi.org/10.1182/blood.V110.11.3537.3537

Published: 2007

NARROW

Epigenetic Priming By Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-Cell Lymphoma

Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma

Anti-Tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients with Chronic Lymphocytic Leukemia: NCIC CTG Trial IND.193

Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML)

A Phase II Study of AT9283, an Aurora Kinase Inhibitor, in Patients with Relapased or Refractory Multiple Myloma; NCIC Clinical Trials Group IND.191

Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study

A Phase I/II Open-Label Multicenter Study Of The Cyclin Kinase Inhibitor AT7519M Alone and In Combination With Bortezomib In Patients With Previously Treated Multiple Myeloma

Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL–positive leukemic cells

The Activity of AT9283 in Acute Myeloid Leukemia in Vitro and in the Clinic Is Karyotype Dependent.

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

Outcome of Aurora Kinase Inhibition of Acute Myeloid Leukemia by AT9283 Is Dependent upon the Presence or Absence of Mutations in Type 1 Oncogenic Kinase Signalling Pathways.

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F Myeloproliferative Disease Models.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only